OHB Pediatrics Ltd. d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, and RACC, a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announces that they have entered into a definitive business combination agreement. In connection with consummation of the transaction, which is expected to close by year-end 2026 subject to customary closing conditions, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio, Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol “OAKH”.
Read the full article: Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company //
Source: https://www.globenewswire.com/news-release/2026/07/27/3333485/0/en/oak-hill-bio-and-research-alliance-corporation-iii-announce-business-combination-agreement-to-create-publicly-listed-rare-disease-biotechnology-company-to-advance-antisense-oligonu.html